Axsome Therapeutics Inc (0HKF.L)

Name: Axsome Therapeutics Inc Financial Statements
Creator: Quarter Results

Healthcare | Medical Pharmaceuticals

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$196M

Net Income

-$28.6M

Operating Margin

-15.0%

Free Cash Flow

-$93.4M

Debt / Assets

87.2%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Axsome Therapeutics Inc (0HKF.L).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	195,999,000	170,992,000	150,042,000	121,463,000
Cost of Revenue	12,329,000	11,912,000	13,448,000	9,789,000
Gross Profit	183,670,000	159,080,000	136,594,000	111,674,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	169,297,000	150,235,000	130,280,000	120,787,000
Operating Expenses	213,100,000	205,189,000	173,308,000	168,656,000
Operating Income	-29,430,000	-46,109,000	-36,714,000	-56,982,000
Interest Expense	1,172,000	1,120,000	1,834,000	2,431,000
Income Before Tax	-28,129,000	-47,229,000	-48,933,000	-59,413,000
Income Tax Expense	430,000	0	-960,000	0
Net Income	-28,559,000	-47,229,000	-47,973,000	-59,413,000
Per Share
EPS	-0.56	-0.94	-0.97	-1.22
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Axsome Therapeutics Inc (0HKF.L).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	638,496,000	385,693,000	270,600,000	50,037,106
Cost of Revenue	47,478,000	33,303,000	26,065,000	10,761,768
Gross Profit	591,018,000	352,390,000	244,535,000	39,275,338
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	570,599,000	411,359,000	323,123,000	157,592,156
Operating Expenses	760,253,000	632,952,000	476,360,000	215,276,163
Operating Income	-169,235,000	-280,562,000	-231,825,000	-176,000,820
Interest Expense	6,557,000	6,569,000	6,453,000	7,334,596
Income Before Tax	-183,704,000	-287,131,000	-238,278,000	-187,133,651
Income Tax Expense	-530,000	85,000	960,000	-3
Net Income	-183,174,000	-287,216,000	-239,238,000	-187,133,651
Per Share
EPS	-3.68	-5.99	-5.27	-4.60
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Axsome Therapeutics Inc (0HKF.L).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	322,933,000	315,353,000	386,193,000	200,841,955
Short Term Investments	0	0	0	0
Net Receivables	224,464,000	142,001,000	94,820,000	37,698,868
Inventory	27,938,000	15,732,000	15,135,000	4,319,921
Total Current Assets	588,986,000	485,064,000	504,263,000	245,641,409
Property Plant Equipment	20,858,000	5,967,000	7,618,000	1,142,813
Goodwill and Intangibles	52,561,000	58,936,000	65,328,000	69,970,772
Total Assets	689,805,000	568,498,000	588,236,000	331,476,095
Liabilities
Account Payables	65,537,000	71,997,000	40,679,000	38,605,312
Short Term Debt	72,979,000	3,256,000	1,267,000	424,673
Total Current Liabilities	378,836,000	230,104,000	138,854,000	96,560,798
Long Term Debt	168,316,000	189,699,000	185,105,000	94,258,888
Total Liabilities	601,510,000	511,483,000	397,259,000	221,919,686
Shareholders Equity
Retained Earnings	-1,305,961,000	-1,122,787,000	-835,571,000	-596,332,736
Total Shareholders Equity	88,295,000	57,015,000	190,977,000	109,556,409

Balance sheet annual history for Axsome Therapeutics Inc (0HKF.L).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	322,933,000	315,353,000	386,193,000	200,841,955
Short Term Investments	0	0	0	0
Net Receivables	224,464,000	142,001,000	94,820,000	37,698,868
Inventory	27,938,000	15,732,000	15,135,000	4,319,921
Total Current Assets	588,986,000	485,064,000	504,263,000	245,641,409
Property Plant Equipment	20,858,000	5,967,000	7,618,000	1,142,813
Goodwill and Intangibles	52,561,000	58,936,000	65,328,000	69,970,772
Total Assets	689,805,000	568,498,000	588,236,000	331,476,095
Liabilities
Account Payables	65,537,000	71,997,000	40,679,000	38,605,312
Short Term Debt	72,979,000	3,256,000	1,267,000	424,673
Total Current Liabilities	378,836,000	230,104,000	138,854,000	96,560,798
Long Term Debt	168,316,000	189,699,000	185,105,000	94,258,888
Total Liabilities	601,510,000	511,483,000	397,259,000	221,919,686
Shareholders Equity
Retained Earnings	-1,305,961,000	-1,122,787,000	-835,571,000	-596,332,736
Total Shareholders Equity	88,295,000	57,015,000	190,977,000	109,556,409

Cash flow quarterly history for Axsome Therapeutics Inc (0HKF.L).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-183,174,000	-287,216,000	-239,238,000	-187,133,651
Depreciation & Amortization	9,064,000	7,958,000	6,834,000	5,564,173
Stock Based Compensation	0	0	62,620,000	37,726,158
Change in Working Capital	-23,058,000	33,900,000	-28,392,000	23,669,257
Operating Cash Flow	-93,405,000	-128,410,000	-145,080,000	-116,510,798
Investing Activities
Capital Expenditure	0	-270,000	-582,000	-702,109
Investments	-480,000	-270,000	-582,000	-702,109
Investing Cash Flow	-480,000	-270,000	-582,000	-53,702,109
Financing Activities
Debt Repayment	-7,750,000	-990,000	85,000,000	-44,512,800
Common Stock Issued/Repurchased	126,265,000	40,784,000	258,750,000	242,507,398
Dividends Paid	0	0	0	-531,871
Financing Cash Flow	101,465,000	57,840,000	331,013,000	284,582,008
Summary
Free Cash Flow	-93,405,000	-128,680,000	-145,662,000	-117,212,907
Net Change in Cash	7,580,000	-70,840,000	185,351,000	114,369,101

Cash flow annual history for Axsome Therapeutics Inc (0HKF.L).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-183,174,000	-287,216,000	-239,238,000	-187,133,651
Depreciation & Amortization	9,064,000	7,958,000	6,834,000	5,564,173
Stock Based Compensation	0	0	62,620,000	37,726,158
Change in Working Capital	-23,058,000	33,900,000	-28,392,000	23,669,257
Operating Cash Flow	-93,405,000	-128,410,000	-145,080,000	-116,510,798
Investing Activities
Capital Expenditure	0	-270,000	-582,000	-702,109
Investments	-480,000	-270,000	-582,000	-702,109
Investing Cash Flow	-480,000	-270,000	-582,000	-53,702,109
Financing Activities
Debt Repayment	-7,750,000	-990,000	85,000,000	-44,512,800
Common Stock Issued/Repurchased	126,265,000	40,784,000	258,750,000	242,507,398
Dividends Paid	0	0	0	-531,871
Financing Cash Flow	101,465,000	57,840,000	331,013,000	284,582,008
Summary
Free Cash Flow	-93,405,000	-128,680,000	-145,662,000	-117,212,907
Net Change in Cash	7,580,000	-70,840,000	185,351,000	114,369,101